No Approved Indication for Longevity Use
Placeholder: aging is not a recognized indication by regulators.
- 0: Approved anti-aging drugs (placeholder figure)
- dozens: Trials underway (placeholder figure)
- few: Regulatory bodies engaged (placeholder figure)
- years: Time to approval est. (placeholder figure)
Why longevity lacks an indication
Placeholder: aging is a process, not a disease label.
Placeholder: regulators require disease-specific endpoints.
Physician Off-Label Prescribing Pathway
Placeholder: doctors may legally prescribe approved drugs off-label.
- common: Off-label prescriptions (placeholder figure)
- present: Physician oversight (placeholder figure)
- moderate: Liability exposure (placeholder figure)
- yes: Documentation required (placeholder figure)
How the pathway works
Placeholder: clinician judgment guides off-label use.
Placeholder: supervision lowers risk versus self-access.
Self-Sourced and Online Access Risks
Placeholder: unsupervised online purchasing bypasses safeguards.
- many: Online sellers unverified (placeholder figure)
- elevated: Dosing errors (placeholder figure)
- limited: Legal recourse (placeholder figure)
- low: Patient awareness (placeholder figure)
Risks of bypassing physicians
Placeholder: no clinical vetting of suitability or interactions.
Placeholder: self-sourcing removes key safety checks.
Quality and Counterfeit Concerns
Placeholder: unregulated supply chains invite counterfeits.
- notable: Counterfeit rate est. (placeholder figure)
- high: Potency variance (placeholder figure)
- present: Contamination reports (placeholder figure)
- rare: Testing access (placeholder figure)
Supply chain vulnerabilities
Placeholder: gray-market products lack batch verification.
Placeholder: counterfeit risk rises without physician sourcing.
Informed Consent and Monitoring Importance
Placeholder: monitoring and consent mitigate off-label harms.
- yes: Baseline labs recommended (placeholder figure)
- periodic: Follow-up visits (placeholder figure)
- improves: Adverse event tracking (placeholder figure)
- higher: Patient understanding (placeholder figure)
Why monitoring matters
Placeholder: regular testing catches adverse effects early.
Placeholder: consent plus monitoring is the safest combination.